Company / Revenue
ENDONOVO THERAPEUTICS, INC. Revenue History
FY2011-FY2022 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Revenue
$135.4K
FY2022
5-year range
$73.1K / $310.2K
FY2018-FY2022
Trend
+85.2%
vs FY2021
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Revenue returned to growth in FY2022 after 2 years of decline, reaching $135,355.
Based on SEC 10-K filings.
$135,355 in FY2022 with a 3-year CAGR of -24.1%.
Declined from $165,796 to $135,355 over the past 2 years.
Revenue over time
Growth rates
- 3-Year CAGR
- -24.1%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- 3-year CAGR of -24.1%, indicating a declining trend.
- In FY2022, revenue increased 85.2% year-over-year.
- Peak revenue was recorded in FY2019.
- Lowest revenue in the period was in FY2015.
Company context
Key Data Points
- Altman Z-Score -76.54 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | RevenueValue | YoY GrowthYoY |
|---|---|---|
| FY2022 | $135.4K | +85.2% |
| FY2021 | $73.1K | -55.9% |
| FY2020 | $165.8K | -46.5% |
| FY2019 | $310.2K | +272.5% |
| FY2018 | $83.3K | - |
| FY2016 | - | - |
| FY2015 | $4.3K | -82.4% |
| FY2014 | $24.2K | -46.9% |
| FY2011 | $45.5K | - |
As of FY2022 · SEC 10-K · Updated Jun 29, 2026